Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
- DOI
- 10.1016/s1470-2045(17)30578-8
- Published
- 2017-08-23
- Container
- Lancet Oncol
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s1470-2045-17-30578-8,
title = {Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.},
author = {Dimopoulos MA and Goldschmidt H and Niesvizky R and Joshua D and Chng WJ and Oriol A and Orlowski RZ and Ludwig H and Facon T and Hajek R and Weisel K and Hungria V and Minuk L and Feng S and Zahlten-Kumeli A and Kimball AS and Moreau P.},
year = {2017},
journal = {Lancet Oncol},
doi = {10.1016/s1470-2045(17)30578-8},
url = {https://doi.org/10.1016/s1470-2045(17)30578-8}
}RIS
TY - JOUR TI - Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. AU - Dimopoulos MA AU - Goldschmidt H AU - Niesvizky R AU - Joshua D AU - Chng WJ AU - Oriol A AU - Orlowski RZ AU - Ludwig H AU - Facon T AU - Hajek R AU - Weisel K AU - Hungria V AU - Minuk L AU - Feng S AU - Zahlten-Kumeli A AU - Kimball AS AU - Moreau P. PY - 2017 JO - Lancet Oncol DO - 10.1016/s1470-2045(17)30578-8 UR - https://doi.org/10.1016/s1470-2045(17)30578-8 ER -
APA
MA, D., H, G., R, N., D, J., WJ, C., A, O., RZ, O., H, L., T, F., R, H., K, W., V, H., L, M., S, F., A, Z., AS, K., & P., M. (2017). Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.. Lancet Oncol. https://doi.org/10.1016/s1470-2045(17)30578-8
Source records
- europe-pmc · retrieved 2026-09-26T04:04:27.287Z